Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 04 - 20 save search
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
Published: 2021-04-20 (Crawled : 14:00) - biospace.com/
CYTH | $1.19 -0.83% -0.84% 57K
|
Professional, Scientific, and T...
|
| O: 5.04%
H: 3.01%
C: 1.57%
disease alzheimer phase 2 trial alzheimer’s alzheimer's disease alzheimer's
180 Life Sciences Corp. Announces Collection of All Patient Data for Phase 2b Dupuytren’s Disease Trial
Published: 2021-04-20 (Crawled : 13:00) - biospace.com/
ATNF | $1.87 2.19% 2.14% 20K
|
|
| O: -0.96%
H: 16.0%
C: -2.06%
disease phase 2 life science phase 2b trial
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
Published: 2021-04-20 (Crawled : 12:00) - globenewswire.com
CRBP | $39.12 7.09% 6.62% 280K
|
Health Technology
|
| O: 0.0%
H: 5.79%
C: 3.66%
treatment phase 2 lupus enroll
Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias
Published: 2021-04-20 (Crawled : 12:00) - biospace.com/
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: -10.99%
H: 2.38%
C: -22.2%
genetic phase 1 positive leukemia trial phase 2 phase 3
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
Published: 2021-04-20 (Crawled : 11:00) - biospace.com/
KALV | $11.59 0.78% 0.78% 350K
|
Health Technology
|
| O: -8.11%
H: 13.25%
C: 11.13%
phase 2 trial kvd824
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy
Published: 2021-04-20 (Crawled : 06:00) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.01%
H: 2.16%
C: 1.56%
disease alzheimer phase 2 therapy phase 2b research trial alzheimer’s alzheimer's disease alzheimer's lecanemab
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy
Published: 2021-04-19 (Crawled : 00:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.01%
H: 2.16%
C: 1.56%
disease alzheimer phase 2 therapy phase 2b research trial alzheimer’s alzheimer's disease alzheimer's lecanemab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.